Key result
Antiplatelet treatment is beneficial for acute coronary syndromes, though some patients experience antiplatelet-drug resistance, a phenomenon lacking a definite cause, definition, or treatment.
This review discusses the role of antiplatelet therapy in acute coronary syndromes and highlights the unresolved clinical challenge of antiplatelet-drug resistance.
Answers are grounded in this paper and cite their sources.
Antiplatelet resistance remains clinically challenging in ACS; leaves open the need for standardized definitions and targeted therapies.
latelets play an essential role in the pathogenesis of acute coronary syndromes (ACS). Over the years antiplatelet treatment has evolved, and currently several types of antiplatelet drugs are available, each with their specific pharmacological target and with their specific clinical indications. Although antiplatelet treatment is beneficial for vascular patients as a group, some individual patients appear to derive less benefit. In this context the term antiplatelet-drug resistance has been introduced. To date, however, no definite cause, definition, or treatment has been determined for this phenomenon. These issues will be discussed in this article.
No takes yet. Share an insight, caveat, or question.
Clappers et al. (2005) conducted a review in Acute coronary syndromes. Antiplatelet treatment was evaluated. Antiplatelet treatment is beneficial for acute coronary syndromes, though some patients experience antiplatelet-drug resistance, a phenomenon lacking a definite cause, definition, or treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: